Anti-Mullerian hormone levels of uterine artery embolization in the treatment of patients suffering Myomectomy and uterine leiomyoma
Not Applicable
- Conditions
- utrine fibroids and bleeding.Other specified noninflammatory disorders of uterus
- Registration Number
- IRCT2014020114333N17
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
age 25-40 years; having debilitating complaints such as severe bleeding due to myoma, uterine enlargement up to 16 weeks pregnancy, anemia and pressure on the pelvic organs of patients which candidates her for myomectomy.
Exclusion criteria: probability of pelvic malignancies, ovarian pathologies, pelvic infections; desiring fertility, contrast sensitivity, renal disorders, and systemic autoimmune disorders.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Duration of returning to work. Timepoint: 6 months after discharge. Method of measurement: Asking the patient.;Anti-Mullerian hormone level. Timepoint: Baseline and 6 months after surgery. Method of measurement: Measurement in the laboratory.;Patients’ complaints (hot flush, bleeding, pelvic pain and pressure, urinary problems, etc.). Timepoint: 6 months after intervention. Method of measurement: Asking the patient.;Pain level. Timepoint: One week after intervention. Method of measurement: Asking the patient.;Duration of hospitalization. Timepoint: Discharge date. Method of measurement: Based on patient records.;Cost of treatment. Timepoint: Discharge date. Method of measurement: Based on patient records.
- Secondary Outcome Measures
Name Time Method